Overcome the Challenge of Treating Unmet Medical Needs Caused by Mitochondrial Dysfunction

We are happy to announce that the Mitochondria-Targeted Drug Development Summit, focused on the pursuit of novel effective therapies for mitochondrial disorders/dysfunction, returns for its 2nd edition.

Incorporating insights from leading academics and pioneering biotech, this forum will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage.

From basic research to the clinic, this year’s meeting will examine novel preclinical animal modelling solutions specifically targeting mitochondria, deliver an update on the current leading clinical trials showcasing mitochondrial transfer, mutations, metabolism, quality control, biogenesis, and peroxidation/ oxidation, along with dedicated sessions on the significance on informatics and data sharing for precision medicine.

Join 80+ leading experts as they navigate common challenges and opportunities for treating unmet medical needs caused by mitochondrial dysfunction. Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies.

Great key speakers that touched on a broad range of subjects. It was very informative and interesting to see how many disease areas mitochondria is being targeted.
Scientific Associate, Novartis


Good overview of a developing field. Learned a lot and found colleagues that I will be reaching out to. It was definitely worthwhile attending.
Director - Clinical Research, Revalesio Corporation


Extremely exciting to learn about past and present efforts in the mito field. I enjoyed the large breath of expertise and the high quality of the presentations. I particularly enjoyed the lively and informative panels.
Founder, Frederik's Foundation

Among the Expert Speaker Faculty

Joseph Sarret

President & Chief Executive Officer


Natalie Yivgi-Ohana

Co-Founder & Chief Executive Officer


Reenie McCarthy

Chief Executive Officer

Stealth Biotherapeutics

Selvaraj Nataraja

Senior Director, Translational Research


Our programme director, Ruju Desai is running 13.1 miles at the London Landmarks Half Marathon on 3rd April 2022 for The Lily Foundation to beat mitochondrial disease.

Every day in the UK a child is born with this genetic condition that has no treatment or cure yet. The Lily foundation is dedicated to change this through funding vital research and supporting those affected.

I want to help them and need your help too! Please donate what you can as every penny helps and will give hope.